Anghesom Ghebremedhin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Anghesom Ghebremedhin has a total of 41 co-authors. Here are the top co-authors by number of shared publications:
- Alejandro Campos
Department of Pathology, University of California, San Diego, La Jolla, CA 92093, USA
1 shared publication - Amanda J. Martinot
Cummings School of Veterinary Medicine at Tufts University, North Grafton, MA 01536, USA
1 shared publication Brenda O’cOnnell
Infinity Pharmaceuticals, Cambridge, MA 02138, USA
1 shared publication- Cesar Piedra-Mora
Department of Comparative Pathobiology, Section of Pathology, Tufts University Cummings School of Veterinary Medicine, North Grafton, MA 01536, USA
1 shared publication Courtney Betts
Department of Cell, Developmental, and Cancer Biology, Oregon Health & Science University, Portland, OR 97201, USA
1 shared publication- David A. Cheresh
Department of Pathology, Moores Cancer Center, and Sanford Consortium for Regenerative Medicine, University of California, San Diego, San Diego, California
1 shared publication
Latest Publications
- 3 July 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 16 (754) , eadi6887
PI3Kγ inhibition circumvents inflammation and vascular leak in SARS-CoV-2 and other infections
Virulent infectious agents such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and methicillin-resistant Staphylococcus aureus (MRSA) induce tissue damage that recruits neutrophils, monocyte, and macrophages, leading to T cell exhaustion, fibrosis, vascular leak, epithelial cell depletion, and fatal organ damage. Neutrophils, monocytes, and macrophages recruited to pathogen-infected lungs, including SARS-CoV-2–infected lungs, express phosphatidylinositol 3-kinase gamma (PI3Kγ), a signaling protein that coordinates both granulocyte and monocyte trafficking to diseased tissues and immune-suppressive, profibrotic transcription in myeloid cells. PI3Kγ deletion and inhibition with the clinical PI3Kγ inhibitor eganelisib promoted survival in models of infectious diseases, including SARS-CoV-2 and MRSA, by suppressing inflammation, vascular leak, organ damage, and cytokine storm. These results demonstrate essential roles for PI3Kγ in inflammatory lung disease and support the potential use of PI3Kγ inhibitors to suppress inflammation in severe infectious diseases.
- 3 July 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 16 (754) , eadi6887
PI3Kγ inhibition circumvents inflammation and vascular leak in SARS-CoV-2 and other infections
Virulent infectious agents such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and methicillin-resistant Staphylococcus aureus (MRSA) induce tissue damage that recruits neutrophils, monocyte, and macrophages, leading to T cell exhaustion, fibrosis, vascular leak, epithelial cell depletion, and fatal organ damage. Neutrophils, monocytes, and macrophages recruited to pathogen-infected lungs, including SARS-CoV-2–infected lungs, express phosphatidylinositol 3-kinase gamma (PI3Kγ), a signaling protein that coordinates both granulocyte and monocyte trafficking to diseased tissues and immune-suppressive, profibrotic transcription in myeloid cells. PI3Kγ deletion and inhibition with the clinical PI3Kγ inhibitor eganelisib promoted survival in models of infectious diseases, including SARS-CoV-2 and MRSA, by suppressing inflammation, vascular leak, organ damage, and cytokine storm. These results demonstrate essential roles for PI3Kγ in inflammatory lung disease and support the potential use of PI3Kγ inhibitors to suppress inflammation in severe infectious diseases.